Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, granules, capsules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, chemotherapeutic agents, etc., as well as vitamin preparations. It sells its generic drugs to distributors, wholesalers, and retailers in Japan and the United States. The company was founded in 1929 and is headquartered in Osaka, Japan.

History

Sawai Group was founded in 1951 by Harish Sawai, a passionate chemist and pharmacist. Since then, the company has grown to become a leader in the Indian pharmaceutical industry. The company was one of the first to develop generic drugs and is now an innovator in the development of complex pharmaceuticals, such as oncology biopharmaceuticals, vaccines, and diagnostics. The company also holds the distinction of being the first Indian company to receive approval for an intravenous (IV) formulation and the first to develop vaccines for the Indian market.

Mission

Sawai Group is committed to creating and delivering innovative, affordable and safe healthcare solutions for individuals and families around the world.

Vision

Sawai Group is dedicated to advancing healthcare through the development of new and existing technologies as well as efficient and cost-effective solutions.

Key Team

Mr. Yoshiki Sakurai (Exec. Officer, Group CFO & GM of Group Financial Department)

Mr. Yasushi Kora (Gen. Mang. of PR & Investor Relations Office)

Mr. Seiji Nishimura (Corp. Officer & Group Chief Marketing Officer)

Kazuhiko Soga (Corp. Officer, Group Chief Human Resource Officer & GM of Group HR Department)

Mr. Akira Hamada (Exe. Officer, Group Chief Digital Transformation Officer & Group Deputy Chief Production Officer)

Ms. Nobuko Sugimoto (Group Chief Intellectual Property Officer)

Mr. Toru Terashima (Sr. Exec. Officer, Director and Chief Quality & Safety Officer)

Recognition and Awards

Sawai Group has won multiple awards for its innovative and pioneering development, including the Golden Peacock Award for Excellence in Healthcare and the Global Kalpana Chawla Award for Excellence in Medicine. The company has also been certified for its commitment to responsible business practices, environment and quality control.

References

https://in.investing.com/equities/sawai-pharmaceutical

https://finance.yahoo.com/quote/4887.T/profile?p=4887.T

https://www.crunchbase.com/organization/sawai-pharmaceutical

https://www.sawaigroup.holdings

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Leadership team

Mr. Mitsuo Sawai (Chairman & CEO)

Mr. Kenzo Sawai (Deputy Chairman & Group Chief Branding Officer)

Mr. Kazuhiko Sueyoshi (Pres, Group COO, Group Chief Admin. Officer & Representative Director)

Products/ Services

Biotechnology, Manufacturing, Pharmaceutical

Number of Employees

1,000 - 20,000

Headquarters

Tokyo, Tokyo, Japan

Established

1929

Revenue

Above - 1B

Traded as

TYO:4555

URL

https://www.sawaigroup.holdings

Last updated: Tue Feb 25 2025

We value your privacy

Sawai

Table of content

Summary